The Oncolytic Activity of Myxoma Virus Against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase

Overview

Journal Clin Med Insights Oncol

Publisher Sage Publications

Specialty Oncology

Date 2021 Feb 26

PMID 33633477

Citations 2

Authors

Yanghee Woo

Susanne G Warner

Rula Geha

Marianne M Stanford

Penelope Decarolis

Masmudur M Rahman

Samuel Singer

Grant McFadden

Yuman Fong

Affiliations

Soon will be listed here.

Abstract

Background: Myxoma virus (MYXV) is an oncolytic poxvirus that lacks the gene for 1 of the subunits of ribonucleotide reductase (RR), a crucial DNA synthesis and repair enzyme. The overexpression of RR has been implicated in the invasiveness of several cancers, including soft tissue sarcomas (STS). The purpose of the study was to investigate the oncolytic efficacy of MYXV in STS with different levels of RR expression.

Methods: The oncolytic effect of recombinant MYXV was evaluated in 4 human STS cell lines, LS141 (a dedifferentiated liposarcoma), DDLS8817 (a dedifferentiated liposarcoma), RDD2213 (recurrent dedifferentiated liposarcoma), and HSSYII (a synovial sarcoma) using infectivity and cytotoxicity assays. Following the overexpression of RRM2 by cDNA transfection and silencing of RRM2 by siRRM2 in these STS cell lines, the RRM2 expression levels were analyzed by Western blot.

Results: We observed a direct correlation between viral oncolysis and RRM2 mRNA levels ( = 0.96) in STS. Higher RRM2 expression was associated with a more robust cell kill. Silencing the RRM2 gene led to significantly greater cell survival (80%) compared with the control group ( = .003), whereas overexpression of the RRM2 increased viral oncolysis by 33% ( < .001).

Conclusions: Our results show that the oncolytic effects of MYXV correlate directly with RR expression levels and are enhanced in STS cell lines with naturally occurring or artificially induced high expression levels of RR. Myxoma virus holds promise in the treatment of advanced soft tissue cancer, especially in tumors overexpressing RR.

Citing Articles

Unveiling the Connection: Viral Infections and Genes in dNTP Metabolism.

Lo S, Lai M, Yang C, Li H Viruses. 2024; 16(9).

PMID: 39339888 PMC: 11437409. DOI: 10.3390/v16091412.

Critical role for ribonucleoside-diphosphate reductase subunit M2 in ALV-J-induced activation of Wnt/β-catenin signaling via interaction with P27.

Tang S, Leng M, Tan C, Zhu L, Pang Y, Zhang X J Virol. 2023; 97(8):e0026723.

PMID: 37582207 PMC: 10506463. DOI: 10.1128/jvi.00267-23.

References

Singer S, Socci N, Ambrosini G, Sambol E, Decarolis P, Wu Y . Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007; 67(14):6626-36. DOI: 10.1158/0008-5472.CAN-07-0584. View

Chan W, Rahman M, McFadden G . Oncolytic myxoma virus: the path to clinic. Vaccine. 2013; 31(39):4252-8. PMC: 3755036. DOI: 10.1016/j.vaccine.2013.05.056. View

Liang W, Li N, Yuan Z, Qian X, Wang Z . DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2. Mol Carcinog. 2018; 58(4):461-473. DOI: 10.1002/mc.22941. View

Liu X, Zhou B, Xue L, Yen F, Chu P, Un F . Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer. 2007; 6(5):374-81. DOI: 10.3816/CCC.2007.n.007. View

Eilber F, Eilber F, Eckardt J, Rosen G, Riedel E, Maki R . The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004; 240(4):686-95. PMC: 1356470. DOI: 10.1097/01.sla.0000141710.74073.0d. View

Weng M, Gong W, Ma M, Chu B, Qin Y, Zhang M . Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Mol Cancer. 2014; 13:82. PMC: 4021541. DOI: 10.1186/1476-4598-13-82. View

Zhu Z, Jin Z, Deng Y, Wei L, Yuan X, Zhang M . Co-expression Network Analysis Identifies Four Hub Genes Associated With Prognosis in Soft Tissue Sarcoma. Front Genet. 2019; 10:37. PMC: 6369179. DOI: 10.3389/fgene.2019.00037. View

Li J, Pang J, Liu Y, Zhang J, Zhang C, Shen G . Suppression of RRM2 inhibits cell proliferation, causes cell cycle arrest and promotes the apoptosis of human neuroblastoma cells and in human neuroblastoma RRM2 is suppressed following chemotherapy. Oncol Rep. 2018; 40(1):355-360. DOI: 10.3892/or.2018.6420. View

Warner S, OLeary M, Fong Y . Therapeutic oncolytic viruses: clinical advances and future directions. Curr Opin Oncol. 2017; 29(5):359-365. DOI: 10.1097/CCO.0000000000000388. View

10.

Das B, Roy J, Jain N, Mallick B . Tumor suppressive activity of PIWI-interacting RNA in human fibrosarcoma mediated through repression of RRM2. Mol Carcinog. 2018; 58(3):344-357. DOI: 10.1002/mc.22932. View

11.

Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A . Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. Hum Pathol. 2010; 41(12):1742-8. DOI: 10.1016/j.humpath.2010.06.001. View

12.

Wang L, Meng L, Wang X, Ma G, Chen J . Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2013; 35(3):1899-906. DOI: 10.1007/s13277-013-1255-4. View

13.

Cameron C, Chen L, Barrett J, Cao J, MacAulay C, Willer D . The complete DNA sequence of myxoma virus. Virology. 1999; 264(2):298-318. DOI: 10.1006/viro.1999.0001. View

14.

Lewis J, Antonescu C, Leung D, Blumberg D, Healey J, Woodruff J . Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000; 18(10):2087-94. DOI: 10.1200/JCO.2000.18.10.2087. View

15.

Gammon D, Gowrishankar B, Duraffour S, Andrei G, Upton C, Evans D . Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis. PLoS Pathog. 2010; 6(7):e1000984. PMC: 2900304. DOI: 10.1371/journal.ppat.1000984. View

16.

Phelps M, Yang H, Patel S, Rahman M, McFadden G, Chen E . Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma. Mol Ther Oncolytics. 2018; 11:52-61. PMC: 6197336. DOI: 10.1016/j.omto.2018.09.001. View

17.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

18.

Zhou B, Tsai P, Ker R, Tsai J, Ho R, Yu J . Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 1998; 16(1):43-9. DOI: 10.1023/a:1006559901771. View

19.

Nordlund P, Reichard P . Ribonucleotide reductases. Annu Rev Biochem. 2006; 75:681-706. DOI: 10.1146/annurev.biochem.75.103004.142443. View

20.

Wang G, Barrett J, Stanford M, Werden S, Johnston J, Gao X . Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A. 2006; 103(12):4640-5. PMC: 1450224. DOI: 10.1073/pnas.0509341103. View